1. Home
  2. BEAM vs AGM Comparison

BEAM vs AGM Comparison

Compare BEAM & AGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$26.68

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Federal Agricultural Mortgage Corporation

AGM

Federal Agricultural Mortgage Corporation

HOLD

Current Price

$178.35

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
AGM
Founded
2017
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
1.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
AGM
Price
$26.68
$178.35
Analyst Decision
Strong Buy
Buy
Analyst Count
12
1
Target Price
$48.09
$219.00
AVG Volume (30 Days)
2.0M
83.2K
Earning Date
11-04-2025
11-03-2025
Dividend Yield
N/A
3.29%
EPS Growth
N/A
12.85
EPS
N/A
17.55
Revenue
$55,701,000.00
$377,946,000.00
Revenue This Year
N/A
$14.80
Revenue Next Year
$26.52
$9.98
P/E Ratio
N/A
$10.38
Revenue Growth
N/A
8.81
52 Week Low
$13.53
$155.00
52 Week High
$35.25
$216.35

Technical Indicators

Market Signals
Indicator
BEAM
AGM
Relative Strength Index (RSI) 56.31 56.47
Support Level $25.86 $175.67
Resistance Level $28.10 $186.25
Average True Range (ATR) 1.56 4.35
MACD 0.18 0.35
Stochastic Oscillator 59.09 43.70

Price Performance

Historical Comparison
BEAM
AGM

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About AGM Federal Agricultural Mortgage Corporation

Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.

Share on Social Networks: